PND17 SEVERITY OF ILLNESS AMONG PERSONS WITH AND WITHOUT MULTIPLE SCLEROSIS: AN ANALYSIS OF COST QUINTILES  by Kleinman, NL et al.
level. The primary outcome was the cost per additional quality
adjusted life year (QALY). The incremental cost per additional
pain-controlled day was a secondary economic outcome. Sensi-
tivity analyses were conducted to investigate the robustness of
the results. RESULTS: The total direct cost of treatment over
one-year was $12,691 for Sativex® + SAC and $3,340 for SAC.
The total QALYs for Sativex® + SAC were 0.3793 and 0.2459
for SAC. The ICUR for Sativex® + SAC compared to SAC was
$70,103/QALY. The number of pain controlled days over
a one-year time horizon was 196 for Sativex® + SAC and
122 for SAC. Cost drivers were Sativex® utilization (5
daily sprays = $36,512/QALY; 11 sprays = $80,327/QALY). The
incremental cost per pain-controlled day was $127. CONCLU-
SION: Results indicated that Sativex® + SAC was more expen-
sive than SAC, but provided increased QALYs and pain-control
in MS patients with neuropathic pain.
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OBJECTIVE: To estimate the cost-utility of interferon beta-1b
(IFNB-1b) in the treatment of patients with a clinically isolated
syndrome (CIS) suggestive of multiple sclerosis (MS).
METHODS: We developed a Markov model of the epidemiol-
ogy and treatment of CIS and MS. The model allows users to
simulate outcomes over varying time horizons. A hypothetical
cohort of 1000 patients with incident CIS was speciﬁed, with
initial health states deﬁned by Kurtzke Expanded Disability
Symptom Scale (EDSS). The cohort was assumed alternatively to
be treated with IFNB-1b (250mg eod) following an initial demy-
elinating event suggestive of MS or not treated until conﬁrma-
tion of MS. Data from a published clinical study (BENEFIT)
were used to model EDSS progression over time and transitions
from CIS to MS. Relapses were estimated from BENEFIT and
published natural history data. Following transition to MS, all
patients were assumed to be treated with IFNB-1b until EDSS
6.5. Direct and indirect costs of MS treatment and IFNB-1b
were estimated from published literature and pricing schedules.
Patient utilities were derived from EQ-5D data from BENEFIT,
supplemented by published data deﬁned by EDSS score and
relapse occurrence. Mortality was estimated using life tables
and EDSS data. Costs (2007 currency) and outcomes were dis-
counted at 5% per annum. Sensitivity analyses were performed
on key model parameters. RESULTS: Use of IFNB-1b was asso-
ciated with slower EDSS progression (hence, longer time to MS
diagnosis), and reduced relapse burden. In the base case (Aus-
tralian perspective; 25-year simulation), incremental cost-utility
of IFNB-1b versus no treatment was AUD58,600 (USD$51,400)
per quality-adjusted life year (QALY) gained. Findings were sen-
sitive to years simulated, IFNB-1b cost and treatment effect,
and underlying rate of disease progression. CONCLUSION:
IFNB-1b treatment of patients with CIS apparently offers rea-
sonable value for money relative to many well-accepted health
care interventions.
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OBJECTIVE: Health care expenditures in Medicare are highly
concentrated in a small proportion of beneﬁciaries. The purpose
of this study was to quantify the concentration and persistence of
overall and prescription drug expenditures in individuals with
Alzheimer’s disease (AD) and to determine the characteristics
associated with future expenditure levels. METHODS: Data
were obtained from the 1999–2004 Medicare Current Beneﬁ-
ciary Survey linked with Medicare claims. Elderly, community-
dwelling individuals with AD were rank-ordered by overall and
drug expenditures. The proportion of expenditures accounted for
by the top 10%, top 25% and top 50% of spenders was calcu-
lated. A transition probability matrix was used to illustrate the
change in expenditure percentiles from one year to the next.
Ordered logit models incorporating prior expenditure, Charlson
Comorbidity Index, functional status and other background
covariates were performed to predict the level of subsequent-year
expenditures. RESULTS: The top 10% of spenders accounted for
38%–47% of overall health expenditures and incurred 31%–
36% of overall drug expenditures depending on the year.
One-quarter of the highest-spending 10% for total health expen-
ditures remained in the top decile in the next year, whereas 21%
of them moved to the bottom half in the subsequent year. Half of
the highest 10% of drug spenders retained this rank-
ing and 9% moved to the bottom 50% in the next year.
Prior expenditures and Charlson comorbidity scores, but not
functional status, were strong predictors of the level of future
expenditures. CONCLUSION: Overall health care and drug
expenditures were highly concentrated and persistent over a two-
year period in this AD population. Prescription drug expendi-
tures exhibited less concentration but more persistence than did
overall health expenditures. Results from this study may further
our knowledge of how expected high expenditures in AD
patients may be reduced with improved care coordination and
effective case management.
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Retrospective claims databases often lack disease severity mea-
sures. As a proxy for illness severity, a quintile analysis of
employees with multiple sclerosis (MS) was conducted. A
2001–2007 U.S. health care claims database was used to iden-
tify employees with MS (ICD-9 code=340.XX). Subjects were
followed for 1 year after their index dates, based on the ﬁrst
disease-modifying therapy (DMT) prescription (IFNâ-1a [SC or
IM], IFNâ-1b, or glatiramer acetate) or for those with no
therapy, the average date of those treated. MS-speciﬁc medical
costs were deﬁned as total claims costs with primary ICD-
9=340.XX. MS-speciﬁc drug costs were deﬁned as all DMT
expenditures. Employees were rank ordered by MS-speciﬁc
(medical and drug) costs and assigned to cost quintiles. In total,
765 employees with MS were analyzed, and 71.9% (n = 550)
with lowest cost (Quintile 1) incurred $1593 in MS-speciﬁc
(medical and drug) costs/employee. Quintiles 2–4 (8.9%, 8.0%,
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and 6.8% of patients, respectively) incurred MS-speciﬁc costs
of $12,830, $14,348, and $17,028/employee, respectively.
Finally, employees in Quintile 5 (highest cost, 4.4%, n = 34)
incurred MS-speciﬁc costs of $26,048/employee. Only 18% of
Quintile 1 had DMT, all subjects in Quintiles 2–4 used DMTs,
and 8.8% of Quintile 5 used no DMTs. Although not used for
quintile assignments, “other conditions” costs/employee were
higher in higher cost quintiles, and Quintile 5 non-MS drug
costs/employee were 6.1–8.6 times higher than Quintiles 1–4.
Similarly, indirect costs were generally higher in the more
expensive quintiles. Average ages were similar between quin-
tiles. Quintile 5 was only 47.1% female, while other quintiles
were >60% female. Wide variation in MS-speciﬁc and non-
speciﬁc costs exists among employees with MS. However,
patients in the highest cost quintile may have the most severe
disease, suffer from multiple conditions and receive other drug
treatments. Further investigation is needed to understand the
impact of comorbid conditions on severity.
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OBJECTIVE: Vasospasm is a common complication of aneurys-
mal subarachnoid hemorrhage (SAH), but its economic impact
has not been studied. In this study, we estimated the incremental
impact of angiographic and clinical vasospasm on inpatient costs
and length of stay (LOS) in a cohort of patients hospitalized for
SAH. METHODS: The study cohort consisted of 198 consecu-
tive patients who underwent either endovascular or surgical
treatment for SAH at Duke University Medical Center (DUMC)
from February 1999 to October 2004. Patients were divided into
three subgroups: clinical (+angiographic) vasospasm (n = 64),
angiographic vasospasm only (n = 51), and patients without
vasospasm (n = 83). Direct and overhead inpatient costs were
obtained from the DUMC cost accounting system. Costs for
physician services were assigned using 2006 Medicare reimburse-
ment rates for North Carolina based on CPT codes billed for
physician services provided to patients in the study cohort. Gen-
eralized linear regression models were applied to assess the incre-
mental impact of vasospasm on inpatient costs and LOS while
adjusting for potentially confounding variables. A counterfactual
approach was applied to estimate the adjusted mean cost differ-
ence between subgroups deﬁned by the presence or absence of
vasospasm. RESULTS: The adjusted incremental cost attribut-
able to clinical vasospasm was $41,877, a 41% increase relative
to no vasospasm (95% CI: 23–62%, p < 0.0001). Angiographic
vasospasm was associated with a $24,528 incremental cost, a
24% increase (95% CI: 7–44%, p = 0.0043). LOS was estimated
to be 6.3 days or 39% longer with clinical vasospasm (95% CI:
21–61%, p < 0.0001), and 4.5 days or 28% longer with angio-
graphic vasospasm (95% CI: 9–50%, p = 0.0026) relative to no
vasospasm. Higher costs related to vasospasm remained signiﬁ-
cant after adjusting for differences in LOS. CONCLUSION:
Patients with clinical and/or angiographic vasospasm incur
higher inpatient costs than those without due to longer hospital
stays and receipt of higher intensity care.
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OBJECTIVE: To determine the economic impact of acute medi-
cation overuse among members with migraine or headache
enrolled in a large, national managed care organization (MCO).
METHODS: Commercial MCO members with a diagnosis of
migraine or headache and acute medication prescriptions from
2002–2006 comprised the study population. A novel claims-
based algorithm based on literature review and clinical expert
input was created to establish thresholds of potential overuse.
Two cohorts were identiﬁed: members with evidence of acute
medication overuse (MO) and members without evidence of
medication overuse (non-MO). Cohorts were followed over vari-
able time periods and compared on demographics, comorbidi-
ties, health care resource utilization and costs. RESULTS: A total
of 17,202 individuals met the criteria for medication overuse,
45,659 comprised the non-MO cohort. Most MO patients met
the criteria for medication overuse by exceeding the threshold for
opiates (62%) or triptans (38%). The MO cohort had signiﬁ-
cantly greater migraine/headache-related and all-cause resource
utilization compared with the non-MO cohort. On a per subject
per month basis, all-cause medical costs for the MO cohort were
$1236 compared with $185 for the non-MO cohort (<0.0001);
all-cause pharmacy costs were $483 for the MO cohort and $105
for the non-MO cohort (<0.0001). For migraine/headache-
related medical and pharmacy costs, total medical costs per
subject per month were $209 for the MO cohort and $33
(<0.0001) for the non-MO cohort, while pharmacy costs were
$286 for the MO cohort and $46 (<0.0001) for the non-MO
cohort. CONCLUSION: Members of this MCO with migraine
or headache who overused acute medications utilized more
health care resources and incurred greater costs compared with
members without acute medication overuse. These results
suggest the possibility that alternate treatment strategies that
decrease medication overuse may result in less health care
resource utilization and lower costs.
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OBJECTIVE: Little is known about medical expenditures in the
multiple sclerosis population after the introduction of expensive
disease modifying agents in the 1990s. This study examines new
data from 2000–2005 population-based survey of MS to provide
estimates of health services utilization by disease severity and
controlling for other risk factors. METHODS: We used a sub-
sample (n = 919) of patients with relapsing remitting and second-
ary progressive MS from the Sonya Slifka Longitudinal Multiple
Sclerosis Study that follows a nationally representative cohort of
MS patients. We examined utilization of hospital and outpatient
care, emergency room (ER), therapy, mental health services,
alternative medicine, home health and personal care. For most
utilization categories, we used log-linear negative binomial
regression models to estimate mean utilization, accounted for
possible correlation of observations for the same person by using
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